Keeping an Eye on Enliven Therapeutics Inc (ELVN) After Insider Trading Activity

Enliven Therapeutics Inc’s recently made public that its CHIEF OPERATING OFFICER Patel Anish unloaded Company’s shares for reported $76239.0 on Mar 06 ’24. In the deal valued at $15.64 per share,4,875 shares were sold. As a result of this transaction, Patel Anish now holds 7,472 shares worth roughly $95268.0.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Then, Lyssikatos Joseph P sold 12,000 shares, generating $197,006 in total proceeds. Upon selling the shares at $16.42, the CHIEF SCIENTIFIC OFFICER now owns 0 shares.

Before that, Hohl Benjamin sold 3,250 shares. Enliven Therapeutics Inc shares valued at $55,163 were divested by the CHIEF FINANCIAL OFFICER at a price of $16.97 per share. As a result of the transaction, Hohl Benjamin now holds 0 shares, worth roughly $0.0.

Jefferies initiated its Enliven Therapeutics Inc [ELVN] rating to a Buy in a research note published on March 29, 2023; the price target was $27.

Price Performance Review of ELVN

On Tuesday, Enliven Therapeutics Inc [NASDAQ:ELVN] saw its stock fall -5.42% to $12.75. Over the last five days, the stock has lost -20.51%. Enliven Therapeutics Inc shares have fallen nearly -7.88% since the year began. Nevertheless, the stocks have fallen -39.54% over the past one year. While a 52-week high of $24.22 was reached on 02/27/24, a 52-week low of $9.80 was recorded on 01/17/24. SMA at 50 days reached $15.13, while 200 days put it at $15.46. A total of 0.22 million shares were traded, compared to the trading of 46200.0 shares in the previous session.

Levels Of Support And Resistance For ELVN Stock

The 24-hour chart illustrates a support level at 12.08, which if violated will result in even more drops to 11.40. On the upside, there is a resistance level at 13.51. A further resistance level may holdings at 14.26. The Relative Strength Index (RSI) on the 14-day chart is 33.83, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.15, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 90.02%. Stochastics %K at 7.53% indicates the stock is a buying.

How much short interest is there in Enliven Therapeutics Inc?

A steep rise in short interest was recorded in Enliven Therapeutics Inc stocks on Feb 29, 2024, dropping by -0.83 million shares to a total of 4.33 million shares. Yahoo Finance data shows the prior-month short interest on Jan 31, 2024 was 5.16 million shares. There was a decline of -19.17%, which implies that there is a negative sentiment for the stock. In spite of short shares comprising just 18.70% of the overall stock float, the days-to-cover ratio (short ratio) fell to 31.24.

Most Popular